Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958450 | 0.98 | NPSR1 (0.45) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL3213105 | 0.93 | NPSR1 (0.45) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL1537011 | 0.93 | NPSR1 (0.43) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL16875246 | 0.93 | NPSR1 (0.43) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL1567508 | 0.92 | NPSR1 (0.38) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL2451039 | 0.90 | NPSR1 (0.46) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL22027027 | 0.90 | NPSR1 (0.37) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL1566238 | 0.89 | NPSR1 (0.39) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL21404238 | 0.87 | NPSR1 (0.43) | NPSR1LMNAHSD11B1CYP4F2CYP4A11 | |
| SCHEMBL18891044 | 0.87 | SMN1; SMN2 (0.39) | NPSR1LMNACYP4F2CYP4A11CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | METACRINE, INC. | 2020-06-11 | — | — | US | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-11-08 | — | — | US | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20140350030-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-11-27 | — | — | US | disclosed |
| EP-2654422-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2013-10-30 | — | — | EP | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| WO-2012088365-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088365-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| EP-1794120-B1 | PEPTIDASE INHIBITORS | NUADA LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-7842707-B2 | Peptidase inhibitors | NUADA, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | NUADA, LLC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | NPSR1 4600/4885LMNA 1544/4885HSD11B1 1184/4885 |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | NPSR1 4600/4885LMNA 1544/4885HSD11B1 1184/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NPSR1 4600/4885LMNA 1544/4885HSD11B1 1184/4885 |
| US-20220002309-A1 | SSAO INHIBITORS AND USES THEREOF | AOX1, AOC2, MAOA | NPSR1 1940/4885LMNA 1461/4885HSD11B1 1050/4885 |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | NPSR1 1072/4885LMNA 1886/4885HSD11B1 1086/4885 |
| US-20200181104-A1 | SSAO INHIBITORS AND USES THEREOF | AOX1, AOC2, MAOA | NPSR1 1940/4885LMNA 1461/4885HSD11B1 1050/4885 |
| US-20140350030-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | CBR1, CYCS, CYP3A43 | NPSR1 890/4885LMNA 482/4885HSD11B1 479/4885 |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NPSR1 4600/4885LMNA 1544/4885HSD11B1 1184/4885 |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | DPP3, DPP4, DPP7 | NPSR1 332/4885LMNA 4120/4885HSD11B1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.